Insomnia Market Size to Hit US$ 6.78 Billion, Globally, by 2033 at 2.55% CAGR

Market Overview:

The insomnia market is experiencing rapid growth, driven by rising prevalence of mental health disorders, advancements in sleep technology, and growing aging population. According to IMARC Group's latest research publication, "Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2025-2033", The global insomnia market size was valued at USD 5.34 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 6.78 Billion by 2033, exhibiting a CAGR of 2.55% during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Grab a sample PDF of this report: https://www.imarcgroup.com/insomnia-market/requestsample

Our report includes:

● Market Dynamics
● Market Trends and Market Outlook
● Competitive Analysis
● Industry Segmentation
● Strategic Recommendations

Growth Factors in the Photomask Market

● Rising Prevalence of Mental Health Disorders

The rising prevalence of mental health disorders, including anxiety and depression, is a huge contributing factor in the insomnia market. These disorders disrupt sleep, leading to chronic insomnia. In a 2023 study, more than 40% of the individuals reported sleep disturbances related to their anxiety disorders - which contributes to either the need for insomnia treatments, -or is a current need for therapy. Pharmaceutical companies are developing and launching therapies that target and focusing of insomnia and mental health concerns. A perfect example is two-in-one antidepressants, which also improve sleep. As more people gain a deeper understanding of mental health concerns, more individuals are likely to seek those and related professional services; thus contributing to the growing market for insomnia medication and behavioral therapy.

● Advancements in Sleep Technology

Technological innovations in sleep are creating expansion in the insomnia market with non-drug solutions that dozens (if not hundreds) of companies are providing for consumers. A prime example are wearable devices like the Fitbit and Oura Ring that provide general sleep insights and help users understand what they can do, based on their sleep patterns, to help manage insomnia. In a published case study, researchers showed that users of a sleep-tracking app reported sleep improvement of 20% due to a scripted guided routine. In addition, smart mattresses and AI-based sleep products like offered by Sleep Number, take user data and adjust the environment for the best quality sleep environment. Even though sleep and gaming are typically associated with controlled substances, these new sleep solutions will appeal to the drug-free consumer lifestyle who trends to have a moderate to high socio-economic background - ultimately driving growth in this area ($1.9B market quickly expanding) as players pour capital into "easy to use, yet impactful, data" sleep solutions.

● Growing Aging Population

The global aging population is a key growth factor for the insomnia market, as older adults frequently experience sleep disorders. Age-related changes, such as reduced melatonin production, contribute to insomnia in seniors. For instance, a 2022 survey found that 50% of people over 65 reported difficulty falling asleep. This demographic trend has spurred demand for tailored treatments, including low-dose sleep aids and cognitive behavioral therapy for insomnia (CBT-I). Pharmaceutical firms are also developing safer medications for elderly patients, while healthcare providers expand sleep clinics, ensuring sustained market growth to address this population's needs.

Key Trends in the Photomask Market

● Shift Toward Non-Pharmacological Therapies

A major trend identified in the insomnia market is the shift towards non-drug therapies. As consumers become more concerned with the side effects of sleep medications, specifically their addictive qualities. Cognitve behavioral therapy for insomnia (CBT-I) is increasingly gaining traction, as it is more effective than medication when assessed over a longer time frame. A recent 2023 trial of CBT-I showed that 70% of participants who received CBT-I continued to have better sleep six months after the treatment. Digital & online therapy platforms (e.g., Headspace app) now offer digital guided CBT-I sessions, making therapy more accessible. Since consumers are moving away from drugs and the shift is to a broader holistic health and well-being perspective, we will continue to see innovations in therapies and therapy-based solutions.

● Integration of Telemedicine in Sleep Care

Telemedicine has changed the insomnia market for the better by improving patient access to specialty providers and treatment options. The ability for patients to be diagnosed and treated (e.g., CBT-I) through virtual consultations without stepping into a clinic is significant. The 2024 Teladoc report highlighted that telehealth platforms generally experienced a 30% increase in sleeprelated consultations. This means that follow-up consultations can be accomplished just as effectively via telemedicine and this is especially relevant in rural locations where the access to a sleep specialist is very limited. Telemedicine also provides the option of remote monitoring with inbuilt connected devices - which can improve treatment efficacy. With that stated, as health systems embrace their digital strategy for the future, telemedicine's role within insomnia care continues to grow and the convenience and individualized care will continue to be appreciated by patients.

● Personalized Medicine in Insomnia Treatment

The emergence of personalized medicine is changing the insomnia market as treatments will be tailored based on genetic and lifestyle considerations. Examples of personalized medicine in sleep medicine include the advances in pharmacogenomics allowing doctors to prescribe medications to patients based on their genetic profile, minimizing side effects. For example, a clinical trial in 2023 used genetic testing in melatonin dosing to improve sleep outcome and 60% of the participants had their sleep outcome improved. We are also seeing a rise in artificial intelligence (AI) initiatives to analyze sleep data and provide recommendations based on the data and other factors e.g., bedtime routines or sleep efficiency (what is the sleep quality based on sleep timing and sleep length). The trend of personalized medicine is boosting the insomnia treatment market, attracting investment in precision medicine, increased investment or funding in insomnia treatment, and improved market positioning for satisfaction and opinions for end-user-patient personalized healthcare solutions.

Buy Full Report: https://www.imarcgroup.com/checkout?id=6148&method=1670

Leading Companies Operating in the Insomnia Industry:

● Astellas Pharma Inc.
● Aurobindo Pharma Limited
● Biocodex
● Eisai Co. Ltd.
● Mallinckrodt Pharmaceuticals
● Merck & Co. Inc.
● Neurim Pharmaceuticals Inc.
● Pfizer Inc.
● Sanofi S.A.
● Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
● Takeda Pharmaceutical Company Limited
● Vanda Pharmaceuticals Inc.

Insomnia Market Report Segmentation:

By Therapy Type:

● Non-Pharmacological Therapy
• Hypnotherapy
• Cognitive Behavioral Therapy
• Medical Devices
• Others
● Pharmacological Therapy
• Prescription Sleep Aids
• Over-The-Counter Sleep Aids

The pharmacological therapy segment is driven by rising demand for effective insomnia treatments, pharmaceutical innovations, and the global prevalence of insomnia, with strategic collaborations and regulatory approvals enhancing market growth.

By Drug Class:

● Antidepressants
● Melatonin Antagonist
● Benzodiazepines
● Nonbenzodiazepines
● Orexin Antagonist
● Others

Benzodiazepines lead with 28.9% market share in 2024, driven by demand for effective anxiolytics and sedatives, ongoing research to improve formulations, and the aging population seeking treatments for anxiety and sleep disturbances.

By Distribution Channel:

● Hospital Pharmacies
● Retail Pharmacies
● Drug Stores
● Online Pharmacies

Hospital pharmacies thrive on the need for specialized services in healthcare facilities, while retail pharmacies benefit from accessibility and convenience; drug stores cater to consumer preferences for one-stop shopping, and online pharmacies gain from the adoption of digital health solutions and e-commerce.

Regional Insights:

● North America (United States, Canada)
● Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
● Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
● Latin America (Brazil, Mexico, Others)
● Middle East and Africa

North America holds the largest market share at over 36.4% in 2024, driven by increased awareness and diagnosis of insomnia, a high prevalence of lifestyle factors contributing to sleep disorders, and advances in medical research and technology enhancing treatment efficacy.

Ask Analyst for Sample Report: https://www.imarcgroup.com/request?type=report&id=6148&flag=C

Research Methodology:

The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145

This release was published on openPR.